Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CERILLIANT™ Guaifenesin Impurity Mixture Solution, 0.5-1.0 mg/mL in Acetonitrile (each analyte), Sold by MilliporeSigma™ Supelco™

Certified reference material

Manufacturer:  MilliporeSigma Supelco G0221ML

Catalog No. 01-001-407


Due to product restrictions, please to purchase or view availability for this product.


Description

Description

Guaifenesin, a glyceryl ether of guaiacol, is a key constituent in cold and cough formulations. It belongs to the group of expectorant medicines because of its ability to ease the discomfort caused due to cough by causing an increase in the sputum volume and a simultaneous decrease in its viscosity. Its applications include short term relief in the breathing passageway in various conditions such as allergy, cold, and upper respiratory tract infections. It has also been proposed to be effective in the management of pain in various conditions such as prostatitis, seminal vesiculitis, benign prostatic hypertrophy, prostatic abscess, bladder neck hypertrophy, dysmenorrhea, and urinary tract infection.
Specifications

Specifications

75-05-8
UN 1648 3 / PGII
124.14
-20°C
2°C (35.6°F) - closed cup
C7H8O2
0.5 to 1.0 mg/mL in acetonitrile (each analyte)
Ampule
1 mL
Safety and Handling

Safety and Handling

H332-H319

H312

SDS
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

CERILLIANT is a registered trademark of Cerilliant Corporation